Drug Origin Transparency Act of 2023
2/5/2024, 2:30 PMSummary of Bill HR 3810
Bill 118 HR 3810, also known as the Drug Origin Transparency Act of 2023, aims to increase transparency in the pharmaceutical industry by requiring drug manufacturers to disclose the origin of their products. The bill specifically targets drugs that are imported from foreign countries, requiring manufacturers to provide detailed information on where the drug was produced, processed, and packaged.The legislation also mandates that drug manufacturers disclose any financial relationships they have with foreign entities involved in the production of the drug. This information is intended to help consumers make more informed decisions about the safety and quality of the medications they are taking.
Additionally, the Drug Origin Transparency Act of 2023 includes provisions to strengthen the oversight of drug imports, including increased inspections of foreign manufacturing facilities and stricter penalties for companies that fail to comply with the disclosure requirements. Overall, the bill seeks to improve transparency and accountability in the pharmaceutical industry, ultimately aiming to ensure the safety and efficacy of drugs imported into the United States.
Read the Full Bill
Current Status of Bill HR 3810
Bill HR 3810 is currently in the status of Bill Introduced since June 5, 2023. Bill HR 3810 was introduced during Congress 118 and was introduced to the House on June 5, 2023. Bill HR 3810's most recent activity was Referred to the Subcommittee on Health. as of June 9, 2023Bipartisan Support of Bill HR 3810
Total Number of Sponsors
1Democrat Sponsors
1Republican Sponsors
0Unaffiliated Sponsors
0Total Number of Cosponsors
8Democrat Cosponsors
8Republican Cosponsors
0Unaffiliated Cosponsors
0Policy Area and Potential Impact of Bill HR 3810
Primary Policy Focus
HealthPotential Impact Areas
Consumer affairsGovernment information and archivesManufacturingPrescription drugsAlternate Title(s) of Bill HR 3810
Drug Origin Transparency Act of 2023Drug Origin Transparency Act of 2023To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes.Comments
Most relevant
Sponsors and Cosponsors of HR 3810
Latest Bills
To require the Committee on Foreign Investment in the United States to review any purchase or lease of real estate near a military installation or military airspace in the United States by a foreign person connected to or subsidized by the Russian Federation, the People's Republic of China, the Islamic Republic of Iran, or the Democratic People's Republic of Korea, and for other purposes.
Bill HR 2754April 19, 2025
Renewable Natural Gas Incentive Act of 2025
Bill S 1252April 19, 2025
A bill to withdraw certain Bureau of Land Management land from mineral development.
Bill S 1464April 19, 2025
A bill to amend the Internal Revenue Code of 1986 to modify the exception for de minimis payments by third party settlement organizations.
Bill S 1425April 19, 2025
A bill to require an annual report of Federal employees and retirees with delinquent tax debt.
Bill S 1444April 19, 2025
To direct the Secretary of Veterans Affairs and the Comptroller General of the United States to report on certain funding shortfalls in the Department of Veterans Affairs.
Bill HR 1823April 19, 2025
To reauthorize the Junior Duck Stamp Conservation and Design Program Act of 1994.
Bill HR 1098April 19, 2025
Cellphone Jamming Reform Act of 2025
Bill S 1137April 19, 2025
A bill to provide for increases in the Federal minimum wage, and for other purposes.
Bill S 1332April 19, 2025
Farmers’ Market Expansion Act of 2025
Bill HR 2379April 19, 2025
Protecting PAHPA Act of 2023
Bill HR 4697February 5, 2024